3D-QSAR (CoMFA and CoMSIA) and pharmacophore (GALAHAD) studies on the differential inhibition of aldose reductase by flavonoid compounds

Journal of Molecular Graphics and Modelling

Volumn 29, Issue 3, 2010, Pages 363-371

  Caballero, Julio ^a  

^a UNIVERSIDAD DE TALCA   (Chile)

Author keywords

Aldose reductase; CoMFA; CoMSIA; Flavonoids; GALAHAD; Inhibitory activity; Pharmacophore; QSAR

Indexed keywords

ALDOSE REDUCTASE; COMFA; COMSIA; FLAVONOIDS; GALAHAD; INHIBITORY ACTIVITY; PHARMACOPHORES; QSAR;

COMPLEXATION; HYDROGEN; HYDROGEN BONDS; MOLECULAR GRAPHICS; PHARMACODYNAMICS;

THREE DIMENSIONAL;

ALDEHYDE REDUCTASE; FLAVONOID;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; COMPUTER MODEL; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

ALDEHYDE REDUCTASE; ENZYME INHIBITORS; FLAVONOIDS; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78649503741     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2010.08.005     Document Type: Article

References (39)

1. Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp. Diabetes Res. 2007, 2007:61038.
2. Chung S.S., Ho E.C., Lam K.S., Chung S.K. Contribution of polyol pathway to diabetes-induced oxidative stress. J. Am. Soc. Nephrol. 2003, 14:S233-236.
3. Kyselova Z., Stefek M., Bauer V. Pharmacological prevention of diabetic cataract. J. Diabetes Complications 2004, 18:129-140.
4. Y. Hamada, J. Nakamura, Clinical potential of aldose reductase inhibitors in diabetic neuropathy, Treat. Endocrinol. 3 (2004) 245-255.
5. Forbes J.M., Coughlan M.T., Cooper M.E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57:1446-1454.
6. S. Miyamoto, Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications, Expert Opin. Ther. Patents 12 (2002) 621-631.
7. Stefanic-Petek A., Krbavcic A., Solmajer T. QSAR of flavonoids. 4. Differential inhibition of aldose reductase and p56lck protein tyrosine kinase. Croat. Chem. Acta 2002, 75:517-529.
8. Okuda J., Miwa I., Inagaki K., Horie T., Nakayama M. Inhibition of aldose reductases from rat and bovine lenses by flavonoids. Biochem. Pharmacol. 1982, 31:3807-3822.
9. Matsuda H., Morikawa T., Toguchida I., Yoshikawa M. Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem. Pharm. Bull. 2002, 50:788-795.
10. Koukoulitsa C., Bailly F., Pegklidou K., Demopoulos V.J., Cotelle P. Evaluation of aldose reductase inhibition and docking studies of 6′-nitro and 6′,6″-dinitrorosmarinic acids. Eur. J. Med. Chem. 2010, 45:1663-1666.
11. Bruno G., Costantino L., Curinga C., Maccari R., Monforte F., Nicolò F., et al. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg. Med. Chem. 2002, 10:1077-1084.
12. Hotta N., Akanuma Y., Kawamori R., Matsuoka K., Oka Y., Shichiri M., et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy. Diabetes Care 2006, 29:1538-1544.
13. Inskeep P, Ronfeld R., Peterson M., Gerber N. Pharmacokinetics of the aldose reductase inhibitor, zopolrestat, in humans. J. Clin. Pharmacol. 1994, 34:760-766.
14. Gonzalez A.M., Sochor M., McLean P. The effect of an aldose reductase inhibitor (Sorbinil) on the level of metabolites in lenses of diabetic rats. Diabetes 1983, 32:482-485.
15. Akamine E.H., Hohman T.C., Nigro D., Carvalho M.H.C., Tostes R.D.C., Fortes Z.B. Minalrestatan aldose reductase inhibitor. Corrects the impaired microvascular reactivity in diabetes. J. Pharmacol. Exp. Ther. 2003, 304:1236-1242.
16. Tanaka Y., Sawamoto T., Suzuki A., Kimura T. Pharmacokinetics of zenarestat, an aldose reductase inhibitor, in male and female diabetic rats. Drug Metabol. Dispos. 1993, 21:677-681.
17. H. Kubinyi, QSAR: hansch analysis and related approaches, In: Methods and Principles in Medicinal Chemistry, R. Mannhold, P. Krokgsgaard-Larsen, H. Timmerman (Eds.), Weinheim, VCH, 1993.
18. Prabhakar Y.S., Gupta M.K., Roy N., Venkateswarlu Y. A high dimensional qsar study on the aldose reductase inhibitory activity of some flavones: topological descriptors in modeling the activity. J. Chem. Inf. Model. 2006, 46:86-92.
19. Mercader A.G., Duchowicz P.R., Fernández F.M., Castro E.A., Bennardi D.O., Autino J.C., et al. QSAR prediction of inhibition of aldose reductase for flavonoids. Bioorg. Med. Chem. 2008, 16:7470-7476.
20. Liu H., Liu S., Qin L., Mo L., CoMFA CoMSIA analysis of 2,4-thiazolidinediones derivatives as aldose reductase inhibitors. J. Mol. Model. 2009, 15:837-845.
21. Thareja S., Aggarwal S., Bhardwaj T.R., Kumar M. 3D-QSAR studies on a series of 5-arylidine-2,4-thiazolidinediones as aldose reductase inhibitors: a self-organizing molecular field analysis approach. Med. Chem. 2010, 6:30-36.
22. Fernández M., Caballero J., Helguera A.M., Castro E.A., González M.P. Quantitative structure-activity relationship to predict differential inhibition of aldose reductase by flavonoid compounds. Bioorg. Med. Chem. 2005, 13:3269-3277.
23. Patra J.C., Singh O. Artificial neural networks-based approach to design ARIs using QSAR for diabetes mellitus. J. Comput. Chem. 2009, 30:2494-2508.
24. Hu L., Chen G., Chau R.M. A neural networks-based drug discovery approach and its application for designing aldose reductase inhibitors. J. Mol. Graph. Model. 2006, 24:244-253.
25. Cramer R.D., Patterson D.E., Bunce J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110:5959-5967.
26. Klebe G., Abraham U., Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37:4130-4146.
27. Richmond N.J., Abrams C.A., Wolohan P.R.N., Abrahamian E., Willett P., Clark R.D. GALAHAD. 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D. J. Comput. Aided Mol. Des. 2006, 20:567-587.
28. Okuda J., Miwa I., Inagaki K., Horie T., Nakayama M. Inhibition of aldose reductase by 3′,4′-dihydroxyflavones. Chem. Pharm. Bull. 1984, 32:767-772.
29. Kador P.F., Kinoshita J.H., Sharpless N.E. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J. Med. Chem. 1985, 28:841-849.
30. Varma S.D., Kinoshita J.H. Inhibition of lens aldose reductase by flavonoids - their possible role in the prevention of diabetic cataracts. Biochem. Pharmacol. 1976, 25:2505-2513.
31. Kador P.F., Kinoshita J.H., Tung W.H., Chylack L.T. Differences in the susceptibility of various aldose reductases to inhibition. II. Invest. Ophthalmol. Vis. Sci. 1980, 19:980-982.
32. SYBYL, version 7.3, 1699 South Hanley Rd., St. Louis, MO 63144, USA, Tripos Inc., SD.
33. Bush B.L., Nachbar R.B. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J. Comput. Aided Mol. Des. 1993, 7:587-619.
34. Richmond N.J., Willett P., Clark R.D. Alignment of three-dimensional molecules using an image recognition algorithm. J. Mol. Graph. Model. 2004, 23:199-209.
35. Gillet V.J., Khatib W., Willett P., Fleming P.J., Green D.V.S. Combinatorial library design using a multiobjective genetic algorithm. J. Chem. Inf. Comput. Sci. 2002, 42:375-385.
36. Clark R., Abrahamian E. Using a staged multi-objective optimization approach to find selective pharmacophore models. J. Comput. Aided Mol. Des. 2009, 23:765-771.
37. Caballero J., Saavedra M., Fernández M., González-Nilo F.D. Quantitative structure-activity relationship of rubiscolin analogues as δ opioid peptides using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). J. Agric. Food Chem. 2007, 55:8101-8104.
38. Caballero J., Fernández M., Saavedra M., González-Nilo F.D. 2D autocorrelation, CoMFA, and CoMSIA modeling of protein tyrosine kinases' inhibition by substituted pyrido[2,3-d]pyrimidine derivatives. Bioorg. Med. Chem. 2008, 16:810-821.
39. Dorfman R.J., Smith K.M., Masek B.B., Clark R.D. A knowledge-based approach to generating diverse but energetically representative ensembles of ligand conformers. J. Comput. Aided Mol. Des. 2007, 22:681-691.